Organization (Industry)
COLLEGIUM PHARMACEUTICAL, INC
ClinicalTrials.gov lists COLLEGIUM PHARMACEUTICAL, INC as lead sponsor of 29 trials, counting the companies grouped under it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. Companies grouped under this one are not included. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 1 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 0.2 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers COLLEGIUM PHARMACEUTICAL, INC and 2 companies grouped under it: 29 lead-sponsored trials (1 its own, 28 in the grouped companies) and 3 legal-entity registrations (2 its own, 1 in the grouped companies).
Companies grouped under this page (2)
Shown in this order: most lead trials first.
| Company | Lead trials | Legal entities |
|---|---|---|
| BioDelivery Sciences International (United States) | 21 | 1 |
| Ironshore Pharmaceuticals and Development, Inc | 7 | 0 |
Disease areas (7)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Attention Deficit Disorder with Hyperactivity | 2 |
| Chronic Pain | 2 |
| Pain | 2 |
| Back Pain | 1 |
| Low Back Pain | 1 |
Showing 5 of 7 disease areas.
Trials by start year as sponsor or collaborator (4)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2024 | 1 |
| 2018 | 1 |
| 2012 | 1 |
Recruitment duration, a model prediction: none of the 1 trial evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Journals published in (8)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Pain | 3 |
| Anesthesiology | 1 |
| Current medical research and opinion | 1 |
| Current therapeutic research, clinical and experimental | 1 |
| Drugs & aging | 1 |
Showing 5 of 8 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 28 | 0 | 2020-06-02 |
SEC-reported annual financials (11)
Shown in this order: newest fiscal year first; SEC EDGAR XBRL companyfacts, USD as reported.
| Fiscal year | Revenue (USD) | Net income (USD) | R&D (USD) |
|---|---|---|---|
| 2025 | 780,567,000 | 62,870,000 | not reported |
| 2024 | 631,449,000 | 69,190,000 | 0 |
| 2023 | 566,767,000 | 48,155,000 | 0 |
| 2022 | 463,933,000 | -25,002,000 | 3,983,000 |
| 2021 | 276,868,000 | 71,517,000 | 9,451,000 |
| 2020 | 310,016,000 | 26,752,000 | 9,772,000 |
| 2019 | 296,701,000 | -22,722,000 | 10,340,000 |
| 2018 | 280,413,000 | -39,128,000 | 8,661,000 |
| 2017 | 28,476,000 | -74,865,000 | 8,572,000 |
| 2016 | 1,711,000 | -94,176,000 | 14,948,000 |
Showing 10 of 11 fiscal years.
Financing and grant events (27)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2026-05-12 | Debt financing | 300,000,000 | Sec extracted |
| 2026-05-12 | Other financing | not disclosed | Sec extracted |
| 2026-03-19 | Other financing | not disclosed | Sec extracted |
| 2025-12-23 | Debt financing | 580,000,000 | Sec extracted |
| 2025-05-12 | Other financing | not disclosed | Sec extracted |
Showing 5 of 27 events.
FDA untitled letters (1)
| Issue date | Letter |
|---|---|
| 2018-02-09 | 111101 |
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| NAI | 3 |
Climate targets, as filed (1)
| Reporting year | Net-zero target |
|---|---|
| 2025 | not disclosed |
Workforce and board diversity, as filed (1)
| Reporting year | Workforce % women | Board % women |
|---|---|---|
| 2025 | not disclosed | not disclosed |
Latest dated events (65)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2027-01 | PDUFA decision date | Regulatory decision dates extracted from SEC filings |
| 2026-11 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-05-12 | Debt facility | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2026-05-12 | Financing | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2026-03-19 | Financing | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
Showing 5 of 65 events.
Biomarker capability evidence (30)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| KIF22 | Trial collaborator | Named in trial inclusion criteria |
| CYP3A4 | Trial collaborator | Named in trial exclusion criteria |
| ERVK-10 | Trial collaborator | Named in trial exclusion criteria |
| ERVK-18 | Trial collaborator | Named in trial exclusion criteria |
| ERVK-19 | Trial collaborator | Named in trial exclusion criteria |
Showing 5 of 30 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: related companies not grouped here, active development programs, approved assets, sponsor delivery record, fda warning letters, fda recalls, fda import refusals, manufacturing and distribution sites, organization relationships, clia clinical laboratory certificates, and biomarkers this organization publishes on.